The ARTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ARTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ARTH Detailed Price Forecast - CNN Money||View ARTH Detailed Summary - Google Finance|
|View ARTH Detailed Summary - Yahoo! Finance||View ARTH Stock Research & Analysis - Zacks.com|
|View ARTH Trends & Analysis - Trade-Ideas||View ARTH Major Holders - Barrons|
|View ARTH Call Transcripts - NASDAQ||View ARTH Breaking News & Analysis - Seeking Alpha|
|View ARTH Annual Report - CompanySpotlight.com||View ARTH OTC Short Report - OTCShortReport.com|
|View ARTH Fundamentals - TradeKing||View ARTH SEC Filings - Bar Chart|
|View Historical Prices for ARTH - The WSJ||View Performance/Total Return for ARTH - Morningstar|
|View the Analyst Estimates for ARTH - MarketWatch||View the Earnings History for ARTH - CNBC|
|View the ARTH Earnings - StockMarketWatch||View ARTH Buy or Sell Recommendations - MacroAxis|
|View the ARTH Bullish Patterns - American Bulls||View ARTH Short Pain Metrics - ShortPainBot.com|
|View ARTH Stock Mentions - StockTwits||View ARTH Stock Mentions - PennyStockTweets|
|View ARTH Stock Mentions - Twitter||View ARTH Investment Forum News - Investor Hub|
|View ARTH Stock Mentions - Yahoo! Message Board||View ARTH Stock Mentions - Seeking Alpha|
|View Insider Transactions for ARTH - SECform4.com||View Insider Transactions for ARTH - Insider Cow|
|View ARTH Major Holdings Summary - CNBC||View Insider Disclosure for ARTH - OTC Markets|
|View Insider Transactions for ARTH - Yahoo! Finance||View Institutional Holdings for ARTH - NASDAQ|
|View ARTH Stock Insight & Charts - FinViz.com||View ARTH Investment Charts - StockCharts.com|
|View ARTH Stock Overview & Charts - BarChart||View ARTH User Generated Charts - Trading View|
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
Posted on Friday June 29, 2018
Arch Therapeutics, Inc. (ARTH) (“Arch” or the “Company”), a developer of innovative materials as hemostatic and wound care devices, today announced the pricing of registered direct offering of 9.1 million units, each unit consisting of a share of the Company’s common stock, and a Series G Warrant (“Series G Warrant”) to purchase 0.75 of a share of our common stock for the combined purchase price of $0.50 per unit. The Series G Warrants have an exercise price of $0.70 per share and are exercisable for a period of five years. Actual results could differ from those projected in any forward-looking statements due to numerous factors.
Arch Therapeutics Provides Skin Sensitization Study Status Update
Posted on Tuesday June 26, 2018
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, provided an update today in which it announced that in the recently initiated skin sensitization study of AC5TM Topical Gel (AC5), two-thirds of the applications of AC5 in the repeat dosing induction phase have occurred and the study remains on schedule. The study, designed as a single-center, prospective, clinical investigation, in approximately 50 healthy subjects, comprises an induction phase separated from a challenge phase by a rest period. During the induction phase, AC5 on a patch is applied to each subject’s back three times weekly over 21 days for a total of 9 applications.
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
Posted on Friday June 15, 2018
Arch Therapeutics, Inc. (ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, announced today that it has completed enrollment for its human skin sensitization study and that applications of the Company’s AC5™ Topical Gel are underway for all subjects. Terrence W. Norchi, MD, President and CEO of Arch, said, "This study is an important component of our plans to address the request by the Food and Drug Administration (FDA or “the Agency”). The Agency had requested further evidence beyond that which was previously supplied to support that AC5 does not cause sensitization in humans.
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
Posted on Tuesday May 15, 2018
FRAMINGHAM, Mass., May 15, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 8 th LD Micro Invitational. ...